Patients with vitiligo or alopecia areata had lower BMI and lipid dysregulation, but this relationship was not observed in patients with psoriasis.

In an exclusive interview, La La Anthony talks about her plaque psoriasis journey, her path to greater confidence, and more.

Discover the latest industry insights at the 2025 Annual Meeting through engaging educational and product-focused sessions. These presentations give exhibiting companies a platform to unveil ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

A new study suggests that dietary changes could play a key role in managing psoriasis severity. Researchers found that a ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA ® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...